Navigation Links
Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
Date:5/5/2008

NEW ROCHELLE, N.Y., May 5 /PRNewswire/ -- Biotech and pharma companies are increasingly utilizing novel technologies to assess the druggability of test compounds early in the development cycle to avoid costly late clinical-stage attrition, according to Genetic Engineering and Biotechnology News (GEN) (http://www.genengnews.com/). By identifying absorption, distribution, metabolism, excretion, and toxicity (ADMET) issues early, pharma also has the opportunity to increase the probability of success of its new drug development activities and reduce the time to market, reports the May 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2460).

"With new drug development costs estimated at over $1 billion, it's imperative that biotech and pharma firms use ADMET tools intelligently and as early as possible in the drug discovery and development process to get a better handle on costs," notes John Sterling, Editor-in-Chief, GEN. "The intelligent application of ADMET studies could also go a long way to improving clinical trial results."

UCB Pharma, for example, uses a suite of validated assays and protocols to monitor the toxic characteristics of all small molecule compounds in its drug discovery pipeline. The company's in vitro toxicology team relies on cell-based assays to assess the cytotoxic potential of drug candidates using cell lines derived from human and rat hepatocytes.

CeeTox, a contract research organization, also takes a cell-based approach when looking at toxicity potential using a number of different cell models to assess not only hepatocellular-based toxic potential but also cardiotoxicity. The company introduced the use of neonate rat cardiomyocytes cultured in 96-well plates to monitor the potential for cardiotoxicity of a drug candidate.

Other companies covered in the GEN article include Affymetrix, Iconix, Sovicell, Apredica, MatTek, ChanTest, and EggCentris.

For a copy of the May 1, 2008 issue of GEN, please call (914) 740-2122, or e-mail: ebicovny@liebertpub.com

Genetic Engineering and Biotechnology News (http://www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.

Contact: John Sterling, Editor-in-Chief, GEN, Phone: 914-740-2196, Cell: 646-234-5118, E-mail: jsterling@genengnews.com


'/>"/>
SOURCE Genetic Engineering and Biotechnology News
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE genetics Announces First Quarter 2008 Financial Results
2. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
3. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
4. deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information
5. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
6. Genetic Testing for All: QTrait Offers Industrys Least Expensive, Most Secure DNA Tests With TRUSTe Certification
7. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
8. Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research
9. Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays
10. Genetic Engineering and Biotechnology News (GEN) Blog: International Students in the United States - A Diminishing Pool of Talent for Biotech?
11. Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... MedGenome,s Commitment Will Help ... of Complex Diseases Such as Cancer, Metabolic Disorders, ... --> --> MedGenome, the market ... leading provider of genomics research services globally, today ... GenomeAsia 100K consortium as a founding member. ...
(Date:2/11/2016)... , Germany and ... QGEN ; Frankfurt Prime Standard: QIA) today ... Targeted RNA Panels for gene expression profiling, expanding QIAGEN,s ... (NGS). The panels enable researchers to select from over ... changes and discover interactions between genes, cellular phenotypes and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics, ... sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in the ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... more than 150 years, continues today to pursue the highest level of accuracy ... analytical instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... with fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... --> --> January to ... up 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
Breaking Biology News(10 mins):